| SC 13G/A | 2023-02-14 | Palo Alto Investors LP | Epizyme, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-09-08 | PRIMECAP MANAGEMENT CO/CA/ | Epizyme, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2022-08-15 | Ipsen, S.A. | Epizyme, Inc. | 1,000 | 100.0% | EDGAR |
| SC 13G/A | 2022-08-09 | PRIMECAP MANAGEMENT CO/CA/ | Epizyme, Inc. | 15,598,934 | 9.3% | EDGAR |
| SC 13D | 2022-07-07 | Ipsen, S.A. | Epizyme, Inc. | 34,419,711 | 20.5% | EDGAR |
| SC 13D/A | 2022-06-28 | RPI Finance Trust | Epizyme, Inc. | 34,419,711 | 20.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Redmile Group, LLC | Epizyme, Inc. | 3,832,475 | 3.5% | EDGAR |
| SC 13G/A | 2022-02-14 | Palo Alto Investors LP | Epizyme, Inc. | 5,485,213 | 5.3% | EDGAR |
| SC 13G/A | 2022-02-10 | PRIMECAP MANAGEMENT CO/CA/ | Epizyme, Inc. | 15,347,777 | 9.4% | EDGAR |
| SC 13G/A | 2022-02-10 | VANGUARD GROUP INC | Epizyme, Inc. | 5,984,908 | 5.8% | EDGAR |
| SC 13G/A | 2022-02-09 | BlackRock Inc. | Epizyme, Inc. | 7,797,036 | 4.8% | EDGAR |
| SC 13G/A | 2022-02-08 | PRIMECAP MANAGEMENT CO/CA/ | Epizyme, Inc. | 15,366,477 | 14.8% | EDGAR |
| SC 13D/A | 2022-02-07 | HUTCHMED (China) Ltd | Epizyme, Inc. | 5,653,000 | 3.4% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | Epizyme, Inc. | 7,615,648 | 7.3% | EDGAR |
| SC 13D/A | 2022-02-01 | RPI Finance Trust | Epizyme, Inc. | 34,367,495 | 21.1% | EDGAR |
| SC 13D | 2021-08-16 | HUTCHMED (China) Ltd | Epizyme, Inc. | 5,653,000 | 5.2% | EDGAR |
| SC 13G/A | 2021-02-16 | Redmile Group, LLC | Epizyme, Inc. | 10,225,405 | 9.9% | EDGAR |
| SC 13G/A | 2021-02-16 | Palo Alto Investors LP | Epizyme, Inc. | 6,738,913 | 6.6% | EDGAR |
| SC 13G/A | 2021-02-12 | PRIMECAP MANAGEMENT CO/CA/ | Epizyme, Inc. | 15,208,527 | 15.0% | EDGAR |
| SC 13G/A | 2021-02-10 | VANGUARD GROUP INC | Epizyme, Inc. | 7,565,247 | 7.4% | EDGAR |